Review of studies evaluating the effectiveness of risk minimization measures for oncology medicinal products registered in the European Medicines Agency (HMA-EMA) catalogue: findings and lessons learned
Future studies should set success thresholds in advance, use a dual evidence approach to measure outcomes, and consider new methods to increase participant numbers. Feasibility assessments prior to conducting studies are essential for achieving meaningful objectives in oncology risk management.
Authors
- Carla Torre (ORCID: https://orcid.org/0000-0002-5542-9993)
- Jorge Monteiro (ORCID: https://orcid.org/0000-0001-6531-6696)
- João Paulo Fernandes (ORCID: https://orcid.org/0000-0002-1952-9460)
- Bruno Sepodes (ORCID: https://orcid.org/0000-0002-2761-0955)
- Diogo Fraxino de Almeida (ORCID: https://orcid.org/0009-0004-5648-2800)
Institutions
- University of Lisbon (PT)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1080/14740338.2025.2471530
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00